A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/30/2004	US6824822 Residual solvent extraction method and microparticles produced thereby
11/30/2004	US6824790 Capsule, tablet with enteric, protective coatings; bioavailability
11/30/2004	US6824786 Topical applying cosmetic
11/30/2004	US6824773 TWEAK receptor
11/30/2004	US6824769 Compositions comprise alpha-interferon or a derivative thereof and an inosine monophosphate dehydrogenase inhibitor; hepatitis virus
11/30/2004	US6824768 Ribavirin-pegylated interferon alfa induction HCV combination therapy
11/30/2004	US6824763 Anti-fungal powder having enhanced excipient properties
11/30/2004	US6824762 Nasal spray compositions
11/30/2004	US6824761 Anti-asthmatic combinations comprising surface active phospholipids
11/30/2004	CA2524805A1 Use of a compound in the treatment of sleep disorders
11/30/2004	CA2396441C Diclofenamide suspension gel
11/30/2004	CA2362117C A system for cell-based screening
11/30/2004	CA2322540C Process for preparing a protected 4-aminomethyl-pyrrolidin-3-one
11/30/2004	CA2315733C Type 2 helper t cell-selective immune response inhibitors
11/30/2004	CA2305307C Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents
11/30/2004	CA2298245C Matrix controlled release device
11/30/2004	CA2251795C Novel n-aminoalkyl-1-biphenylenyl-2-carboxamides; new dopamine receptor subtype specific ligands
11/30/2004	CA2245142C New phenanthridines
11/30/2004	CA2103062C Oligo-2'-deoxynucleotides and their use as pharmaceutical agents with antiviral activity
11/30/2004	CA2089309C Novel pharmaceutical uses of bilobalide and derivatives thereof and pharmaceutical compositions adapted for such use
11/30/2004	CA2075189C Method and compositions for the synthesis of bch-189 and related compounds
11/27/2004	CA2467410A1 Method for treatment of glaucoma and ocular hypertension with prostaglandin analgoues without melanogenic side-effect
11/27/2004	CA2464379A1 Use of anti-glaucoma drugs to treat visual defects associated with the use of a gabaergic agent
11/25/2004	WO2004102774A1 Dc motor
11/25/2004	WO2004101826A2 Methods to identify compounds that modulate the autoinducer-2 dependent quorum sensing system in vibrio harveyi
11/25/2004	WO2004101787A1 Inhibition of the expression of huntington gene
11/25/2004	WO2004101767A2 Cbi analogues of the duocarmycins and cc-1065
11/25/2004	WO2004101764A2 Methods of modulating metastasis and skeletal related events resulting from metastases
11/25/2004	WO2004101595A1 Estratriene derivatives
11/25/2004	WO2004101593A1 5'-modified nucleoside derivative and medicinal use thereof
11/25/2004	WO2004101591A1 NEW 3-DECLADINOSYL 9a-N-CARBAMOYL AND 9a-N-THIOCARBAMOYL DERIVATIVES OF 9-DEOX-9-DIHYDRO-9a-AZA-9A-HOMOERYTHROMYCIN A
11/25/2004	WO2004101590A1 Novel 14 and 15 membered-ring compounds
11/25/2004	WO2004101589A1 Novel 14 and 15 membered-ring compounds
11/25/2004	WO2004101588A1 Novel 14 and 15 membered ring compounds
11/25/2004	WO2004101587A1 Novel 14 and 15 memberred-ring compounds
11/25/2004	WO2004101586A1 Novel 14 and 15 membered-ring compounds
11/25/2004	WO2004101583A1 Rapamycin carbohydrate derivatives
11/25/2004	WO2004101570A1 Sulfur-containing naphthoylimide derivatives
11/25/2004	WO2004101568A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
11/25/2004	WO2004101556A1 INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
11/25/2004	WO2004101551A1 Crystal of benzimidazole derivative and process for producing the same
11/25/2004	WO2004101547A1 Purification methods of gatifloxacin and a novel form of gatifloxacin
11/25/2004	WO2004101544A1 Benzyl sulfonamide derivatives as androgen receptor antagonists
11/25/2004	WO2004101535A1 Pharmaceutical composition comprising valsartan
11/25/2004	WO2004101529A1 Nitrogenous heterocyclic compound and medical use thereof
11/25/2004	WO2004101522A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
11/25/2004	WO2004101520A1 Diarylmethylidene piperidine derivatives and their use as delta opiod receptor agonists
11/25/2004	WO2004101512A2 Naphthyridine integrase inhibitors
11/25/2004	WO2004101510A2 Polymorphs of cabergoline
11/25/2004	WO2004101506A1 Glyoxalase inhibitors
11/25/2004	WO2004101072A1 Cns chloride modulation and uses thereof
11/25/2004	WO2004100994A2 Method for the production of a stable injectable formulation made of difficult to dissolve antineoplastic active substances
11/25/2004	WO2004100992A2 Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
11/25/2004	WO2004100989A1 Preventives/remedies for snore or respiratory disturbances during sleep
11/25/2004	WO2004100987A2 Methods of using il-1 antagonists to treat neointimal hyperplasia
11/25/2004	WO2004100981A1 One or several enzyme-containing compounds, dietetic food products and drugs produced from said compounds and the use therefor for medical purposes
11/25/2004	WO2004100980A1 Interferon for treating or preventing a coronaviral infection
11/25/2004	WO2004100977A1 Inhibition of tumor cell proliferation by foxm1b inhibitors
11/25/2004	WO2004100973A2 Pharmaceutical compositions of antithrombin iii for the treatment of retroviral diseases.
11/25/2004	WO2004100972A1 Preventive and/or remedy for diseases accompanied by tissue destruction
11/25/2004	WO2004100968A2 A synergistic composition for the treatment of diabetes mellitus
11/25/2004	WO2004100966A1 Preparation for preventing contact of pathogenic matter with living organism
11/25/2004	WO2004100965A1 Immunostimulant
11/25/2004	WO2004100964A1 Method of treating atrial fibrillation or atrial flutter
11/25/2004	WO2004100963A1 A composition containing gensenoside rh2 as an active material for preventing brain cell
11/25/2004	WO2004100962A1 Melanogenesis inhibitory substance
11/25/2004	WO2004100961A1 Sulfate group transferase inhibitor
11/25/2004	WO2004100960A2 Anti-inflammatory phosphonate compounds
11/25/2004	WO2004100959A1 External patch containing estrogen and/or progestogen
11/25/2004	WO2004100957A1 Treatment of bipolar disorders and associated symptoms
11/25/2004	WO2004100956A1 Method for enhancing cognition using ziprasidone
11/25/2004	WO2004100955A1 Anxiety treatments with ziprasidone
11/25/2004	WO2004100954A1 Treatment of psychotic and depressive disorders
11/25/2004	WO2004100953A1 Combination of irinotecan and revimid for the treating multiple myeloma
11/25/2004	WO2004100951A1 Diabetic neuropathy diagnostic and therapeutic
11/25/2004	WO2004100949A2 Solid-state forms of 5-(difluoromethoxy)-2-((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole (pantoprazole) sodium aqua complexes
11/25/2004	WO2004100948A1 Further therapeutic use of zolpidem
11/25/2004	WO2004100947A2 Novel chemical compounds
11/25/2004	WO2004100945A1 Use of phthalide derivatives for the treatment and prevention of diabetes mellitus
11/25/2004	WO2004100944A1 Bicalutamide forms, compositions, and processes thereof
11/25/2004	WO2004100943A1 Use of triglyceride oils containing gamma-linolenic acid residues and linoleic acid residues for the treatment of neurodegenerative disease
11/25/2004	WO2004100942A1 Composition for lowering lipid in body
11/25/2004	WO2004100941A1 Pharmaceutical compositions
11/25/2004	WO2004100940A1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression
11/25/2004	WO2004100939A1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression
11/25/2004	WO2004100938A1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression
11/25/2004	WO2004100937A1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression
11/25/2004	WO2004100936A1 Therapeutic agent
11/25/2004	WO2004100935A2 Propofol formulation containing reduced oil and surfactants
11/25/2004	WO2004100932A1 Controlled drug release composition resistant to in vivo mechanic stress
11/25/2004	WO2004100931A2 Use of soaps such as magnesium stearate for increasing the release of drugs
11/25/2004	WO2004100930A1 Pharmaceutical dosage form comprising a solid solution
11/25/2004	WO2004100896A2 Anti-aging nutritional supplement
11/25/2004	WO2004100895A2 Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
11/25/2004	WO2004100894A2 Drug formulations having reduced abuse potential
11/25/2004	WO2004100893A2 Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
11/25/2004	WO2004100891A2 Cytotoxic indeno and isoindoloisoquinolones
11/25/2004	WO2004100885A2 Compositions and methods for treating cancer
11/25/2004	WO2004100884A2 Oral care methods and products
11/25/2004	WO2004100882A2 Inhibition of drug binding to serum albumin

1 ... 4877 4878 4879 4880 4881 4882 4883 4884 4885 4886 4887 4888 4889 4890 4891 4892 4893 4894 4895 4896 4897 ... 7860